Healthcare entity
Every one of those 1 sits in a single category, medical-devices. Nyxoah is most often covered alongside Alumis, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, medical-devices. Nyxoah is most often covered alongside Alumis, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 2 original sources each against 2.9 for the same window. We currently track 1 Healthcare story that mention Nyxoah, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nyxoah. Shared-story counts are live from our verified record — not editorial picks.
Both Nyxoah and Alumis reported quarterly earnings that missed analyst expectations by $0.04 per share, reflecting the high operational costs of late-stage clinical trials and pre-commercialization activities. Despite the financial shortfall, both companies remain on track with pivotal regulatory and clinical milestones in the sleep apnea and immunology sectors.
Source: tickerreport.com · dailypolitical.com
Nyxoah is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
